Bioinformatic gene analysis for potential biomarkers and therapeutic targets of atrial fibrillation-related stroke

Rongjun Zou†, Dingwen Zhang†, Lei Lv†, Wanting Shi, Zijiao Song, Bin Yi, Bingjia Lai, Qian Chen, Songran Yang* and Ping Hua*

Abstract

Background: Atrial fibrillation (AF) is one of the most prevalent sustained arrhythmias, however, epidemiological data may understate its actual prevalence. Meanwhile, AF is considered to be a major cause of ischemic strokes due to irregular heart-rhythm, coexisting chronic vascular inflammation, and renal insufficiency, and blood stasis. We studied co-expressed genes to understand relationships between atrial fibrillation (AF) and stroke and reveal potential biomarkers and therapeutic targets of AF-related stroke.

Methods: AF-and stroke-related differentially expressed genes (DEGs) were identified via bioinformatic analysis Gene Expression Omnibus (GEO) datasets GSE79768 and GSE58294, respectively. Subsequently, extensive target prediction and network analyses methods were used to assess protein–protein interaction (PPI) networks, Gene Ontology (GO) terms and pathway enrichment for DEGs, and co-expressed DEGs coupled with corresponding predicted miRNAs involved in AF and stroke were assessed as well.

Results: We identified 489, 265, 518, and 592 DEGs in left atrial specimens and cardioembolic stroke blood samples at < 3, 5, and 24 h, respectively. LRRK2, CALM1, CXCR4, TLR4, CTNNB1, and CXCR2 may be implicated in AF and the hub-genes of CD19, FGF9, SOX9, GNGT1, and NOG may be associated with stroke. Finally, co-expressed DEGs of ZNF566, PDZK1IP1, ZFHX3, and PITX2 coupled with corresponding predicted miRNAs, especially miR-27a-3p, miR-27b-3p, and miR-494-3p may be significantly associated with AF-related stroke.

Conclusion: AF and stroke are related and ZNF566, PDZK1IP1, ZFHX3, and PITX2 genes are significantly associated with novel biomarkers involved in AF-related stroke.

Keywords: Gene analysis, Biomarkers, Atrial fibrillation-related stroke

Background

Atrial fibrillation (AF) is one of the most prevalent sustained arrhythmias, having an age-adjusted hospitalization incidence of 1–4% of the general population and an prevalence rising of > 13% for those older than 80-years-of-age [1, 2]. However, epidemiological data may understate its actual prevalence, because 40% of patients are asymptomatic and remain undiagnosed with subclinical AF [3]. There is also evidence that patients with AF have significantly increased cardiovascular-related morbidity, given its association with atrial and ventricular mechanical or electrical failure, structural and hemodynamic alterations, and thromboembolic events [3].

Stroke is the leading cause of disability and death and has an estimated incidence of 3.73 (95% CI 3.51–3.96) per 1000 person-years among black- and white- adults in an atherosclerosis risk in communities (ARIC) cohort [4].
Furthermore, global increases in stroke prevalence plus stroke-related disability and mortality associated with aging will increase [5, 6]. Thus, we may not now know the actual true burden of stroke due to limits in brain imaging identification in < 10 mm small hypointense areas and silent infarctions for 28% of those patients older than 65-years-of-age [7]. AF is commonly classified as paroxysmal, persistent or permanent, or new onset arrhythmia basing on the present continuous time, which mainly included that paroxysmal AF was self-terminates within 7 days, while persistent AF was lasts longer than 7 days or needs cardioversion, and usually has lasted for 3 months [8]. As we all known, AF is considering to be a major cause of ischemic strokes due to irregular heart-rhythm, coexisting chronic vascular inflammation, and renal insufficiency, and blood stasis. According to Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) trial study, Steinberg et al. [9] suggested that the paroxysmal AF patients carrying a lower adjusted rate of stroke or systemic embolism (adjusted HR: 0.78, 95% CI 0.61–0.99, P = 0.045), all-cause mortality (adjusted HR: 0.79, 95% CI 0.67–0.94, P = 0.006), and the composite of stroke or systemic embolism or death (adjusted HR: 0.82, 95% CI 0.71–0.94, P = 0.005) than persistent AF patients after adjusted efficacy and safety outcomes. According to the Oxford vascular study (OXVASC), nearly 43.9% of ischemic strokes were associated with AF among patients 80-years-of-age or older who had a threefold increase in AF in the past 3 decades [10]. However, this assumption has been challenged by the atrial fibrillation reduction atrial pacing trial (ASSERT) which identified a temporal association between subclinical AF and stroke risk among patients with implantable pacemakers and defibrillators. They reported that only 8% and 16% of patients had an association between pre-detected and post-detected AF within months of stroke or systemic embolism, respectively [11]. Of note, AF is often intermittent and asymptomatic, and presents as an electromechanical disassociation of atrial fibrillation. Clinically, current stroke risk scores and traditional diagnosis with an electrocardiogram are practical, while the limitation of predict stroke risk accurately in individual AF patients was significantly identified, especially in persistent AF which carrying a higher risk of stroke or systemic embolism and all-cause mortality [12]. In this study, we identified co-expressed differentially expressed genes (co-DEGs) of persistent AF and stroke and elucidated molecular mechanisms and pathology of AF-related DEGs (AF-DEGs) and stroke-related DEGs (stroke-DEGs). Finally, we provide a bioinformatic analysis of DEGs and predicted microRNAs (miRNAs) for AF patients prone to stroke.

Methods
Materials and methods
GSE79768 and GSE58294 datasets were downloaded from GEO (http://www.ncbi.nlm.nih.gov/geo/) [13] and expression profiling arrays were generated using GPL570 (HG-U133_Plus_2) Affymetrix Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA). Additionally, the GSE79768 dataset, including 26 specimens with paired left atrial (LA) and right atrial (RA) tissue obtained from 13 patients was used to identify differential LA-RA gene expression and molecular mechanisms for patients with persistent AF or sinus rhythm (SR) abnormalities and we describe potential mechanisms of AF-related remodeling in the LA and the relationship between LA arrhythmogenesis and thrombogenesis. In this study, persistent AF patients has lasts continuously for > 6 months, while the SR patients had no evidence of AF clinically and any anti-arrhythmic drug history. Blood samples of GSE58294 were collected from cardioembolic stroke (N = 69) and control patents (N = 23) at < 3, 5, and 24 h.

Data processing
R packages of “affy”, “affyPLM”, and “limma” (http://www.bioconductor.org/packages/release/bioc/html/affy.html), provided by a bioconductor project [14], were applied to assess GSE79768 and GSE58294 RAW datasets. We used background correction, quantile normalization, probe summarization and log2-transformation, to create a robust multi-array average (RMA), a log-transformed perfect match, and a mismatch probe (PM and MM) methods. The Benjamini-Hochberg method was used to adjust original p-values, and the false discovery rate (FDR) procedure was used to calculate fold-changes (FC). Genes expression values of the |log2 FC| > 1 and adjusted p < 0.05 were used for filtering AF-DEGs. However, the |log2 FC| > 1.5 and adjusted p < 0.05 were used to identify stroke-DEGs, given that blood sample specificity pointed to many genes. Additionally, we calculated and made Venn diagrams for co-DEGs for AF- and stroke-DEGs.

Finally, we applied online prediction tools utilizing microRNA Data Integration Portal (mirDIP) (http://ophid.utoronto.ca/mirDIP) [15], miRDB (http://mirdb.org/) [16], TargetScan (v7.1; http://www.targetscan.org/vert_71/) [17], and DIANA Tools (http://diana.imis.athena-innovation.gr/DianaTools/) [18], to predict potential microRNA targeting. Subsequently, we used the mirDIP, miRDB, TargetScan, and Diana Tools software to predict which of the selected miRNAs could target co-DEGs. We determined 5 top candidate miRNAs based on higher predicted scores for ≥ 3 prediction tools for each co-DEG.
Identification of protein–protein interaction (PPI) networks of DEGs
PPI networks of AF- and stroke-DEGs were analyzed using the search tool for the retrieval of interacting genes (STRING database, V10.5; http://string-db.org/) that predicted protein functional associations and protein–protein interactions. Subsequently, Cytoscape software (V3.5.1; http://cytoscape.org/) was applied to visualize and analyze biological networks and node degrees, after downloading analytic results of the STRING database with a confidence score > 0.4 [19].

Functional enrichment analysis
Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of AF- and stroke-DEGs were carried out using the database for annotation, visualization and integrated discovery bioinformatics resources (DAVID Gene Functional Classification Tool, http://david.abcc.ncifcrf.gov/) [20], and REACTOME databases (v62; http://www.reactome.org) [21]. GO terms and KEGG maps of biological functions associated with a $p < 0.05$ was considered to be significantly enriched. In addition, we presented different biofunctions of AF- and stroke-DEGs in biological processes, molecular functions, and cellular components from DAVID and REACTOME databases, respectively.

Subsequently, the AmiGO database (v2.0; http://amigo.geneontology.org/ami go/) was used to analyze the GO consortium for selected co-DEGs to verify the accuracy and annotate biofunctions of identified co-DEGs [22]. Using microRNA target prediction, online tools from Diana-miRPath (v3.0; http://www.microrna.gr/mirpathv3) [18] were applied to evaluate interactions between miRNA previously identified using prediction tools and co-DEGs involved in AF and stroke.

Identification of co-DEGs associated with nervous or cardiovascular diseases
The comparative toxicogenomics database (http://ctdbase.org/) was used to find integrated chemical-gene, chemical-disease, and gene-disease interactions to generate expanded networks and predict novel associations [23]. We used these data to analyze relationships between gene products and nervous or cardiovascular diseases. Here, relationships between co-DEGs and diseases and association or an implied association were identified.

Results
Identification of DEGs
We identified 54,674 probes corresponding to 20,484 genes in GSE79768 and GSE58294 datasets and AF- and stroke-DEGs were confirmed. We found 489 DEGs in LA specimens of AF patients compared with SR patients, including 428 down-regulated genes and 61 up-regulated genes. However, total of 265, 518, and 592 DEGs were identified following the time points of less than 3, 5, and 24 h after stroke, respectively. Here, we defined 210 co-expressed DEGs in the three time points mentioned above as the stroke-DEGs. Heatmaps of AF-DEGs in relation to inflammatory and immune response, ion channels, and cell signaling were conducted for genes expression and these data appear in Fig. 1 and Additional file 1: S1. Simultaneously, Fig. 2 and Additional file 2: S2 has shown the genes expression value in relation to inflammatory response, energy metabolism, ions channel and transportation, and neuronal regulation above the stroke-DEGs.

Functional enrichment in Co-DEGs
Figure 3c illustrates expressed AF- and stroke-DEGs and co-expressed genes. Interestingly, four co-expressed DEGs, including zinc finger protein 566 (ZNF566), PDZK1 interacting protein 1(PDZKIIP1), zinc finger homeobox 3 (ZFHX3), paired-like homeodomain 2 (PITX2), were observed. The AmiGO database was used to confirm GO term enrichment related to biological processes, molecular functions, and cellular components and Co-DEGs were associated with various processes as indicated in Table 1.

PPI network analysis and functional GO terms and pathway enrichment analyses
We identified 256 and 43 nodes from PPI network of AF- and stroke-DEGs, respectively and these data appear in Fig. 3. Here, the hub nodes, including leucine-rich repeat kinase 2 (LRRK2; degree = 38), calmodulin 1 (CALM1; degree = 25), chemokine (C-X-C motif) receptor 4 (CXCR4; degree = 25), toll-like receptor 4 (TLR4; degree = 21), catenin (cadherin-associated protein), beta 1 (CTNNB1; degree = 21), and chemokine (C-X-C motif) receptor 2 (CXCR2; degree = 21) are considering as hub-genes in related to AF maintaining. However, the hub-genes, involved in CD19 (degree = 5), fibroblast growth factor 9 (FGF9; degree = 5), SRY (sex determining region Y)-box 9 (SOX9; degree = 5), guanine nucleotide binding protein (G protein), gamma transducing activity polypeptide 1(GNGT1; degree = 4), and noggin (NOG; degree = 4), are demonstrated in stroke-DEGs with a relative higher degree.

Using the DAVID database, the top 5 GO terms related biological processes among those genes were primarily associated with inflammatory response (Fold
Enrichment: 4.08; \( p \) value: 1.11E–07, immune response (Fold Enrichment: 3.50; \( p \) value: 2.49E–06), regulation of MAP kinase activity (Fold Enrichment: 9.53; \( p \) value: 1.92E–05), and regulation of NF-kappa B activity (Fold Enrichment: 16.73; \( p \) value: 1.95E–04). There is significant correlation in plasma membrane (Fold Enrichment: 1.60; \( p \) value: 1.37E–06), extracellular region (Fold Enrichment: 1.75; \( p \) value: 8.88E–04), and MHC class II protein complex (Fold Enrichment: 13.47; \( p \) value: 0.003) in relation to cellular components. In addition, the terms related molecular functions were mainly involved in ion channel binding (Fold Enrichment: 5.06; \( p \) value: 0.001), neuropeptide Y receptor activity (Fold Enrichment: 23.84; \( p \) value: 0.007), and transmembrane...
**Fig. 2** Hierarchical clustering analysis of stroke-related DEGs: a–c results of hierarchical clustering analysis for DEG expression in relation to energy metabolism, ion channel, inflammatory response, and neuronal regulation. Red, greater expression. Blue, less expression. a PPI network of AF-related DEGs; b PPI network of stroke-related DEGs. Red, greater degree. yellow, lesser degree; c Venn diagrams of DEGs.
Table 1 The Gene Ontology (GO) terms enrichment for the co-expressed genes of the AF-related stroke

| Gene/product | GO class (direct)                                      | Evidence  | Evidence with | Reference          |
|--------------|-------------------------------------------------------|-----------|---------------|--------------------|
| PDZK1IP1     | Integral component of membrane                        | IEA       | UniProtKB-KW:KW-0812 | GO_REF:0000037     |
|              | Extracellular exosome                                 | IDA       | PMID:19056867  |                    |
| ZNF566       | DNA binding                                           | IEA       | UniProtKB-KW:KW-0238 | GO_REF:0000037     |
|              | Nucleus                                               | IEA       | UniProtKB-SubCellSL-0191 | GO_REF:0000039     |
|              | Transcription, DNA-templated                          | IEA       | UniProtKB-KW:KW-0804 | GO_REF:0000037     |
|              | Metal ion binding                                     | IEA       | UniProtKB-KW:KW-0479 | GO_REF:0000037     |
| ZFHX3        | Negative regulation of transcription from RNA polymerase II promoter | IGI     | UniProtKB-P01104 | PMID:10318867      |
|              | RNA polymerase II proximal promoter sequence-specific DNA binding | IDA       | PMID:7507260    |                    |
|              | core promoter sequence-specific DNA binding           | ISS       | UniProtKB-Q61329 | GO_REF:0000024     |
|              | Transcriptional repressor activity, RNA polymerase II proximal promoter sequence-specific DNA binding | IC       | GO:0000122/GO:0000978 | GO_REF:0000036     |
|              | Protein binding                                       | IPI       | UniProtKB:Q13761 | PMID:20599712      |
|              | Nucleus                                               | TAS       | PMID:1719379    |                    |
| PITX2        | Transcription regulatory region sequence-specific DNA binding | IDA       | PMID:9685346    |                    |
|              | Transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding | IEA  | UniProtKB:Q9R0W1 | GO_REF:0000107     |
|              | RNA polymerase II transcription coactivator activity  | IDA       | PMID:9685346    |                    |
|              | Branching involved in blood vessel morphogenesis      | IEA       | UniProtKB:P97474 | GO_REF:0000107     |
|              | Vasculogenesis                                        | IEA       | UniProtKB:P97474 | GO_REF:0000107     |
|              | In utero embryonic development                        | IEA       | UniProtKB:P97474 | GO_REF:0000107     |
|              | Neuron migration                                      | IEA       | UniProtKB:P97474 | GO_REF:0000107     |
|              | Extraocular skeletal muscle development               | IEA       | UniProtKB:P97474 | GO_REF:0000107     |

ISS sequence similarity evidence used in manual assertion, IGI genetic interaction evidence used in manual assertion, IDA direct assay evidence used in manual assertion, IEA evidence used in automatic assertion, IPI physical interaction evidence used in manual assertion
receptor protein tyrosine kinase adaptor activity (Fold Enrichment: 21.46; p-value: 0.008). With respect to stroke-DEGs, the biological processes terms of regulation of myoblast differentiation (Fold Enrichment: 25.39; p-value: 4.89E−04), endocardial cushion morphogenesis (Fold Enrichment: 27.38; p-value: 0.005), positive regulation of epithelial cell proliferation (Fold Enrichment: 9.73; p-value: 0.008), and fibroblast growth factor receptor signaling pathway (Fold Enrichment: 7.12; p-value: 0.018) were significantly enriched. Similarly, the terms of RNA polymerase II transcription factor activity, sequence-specific DNA binding (Fold Enrichment: 5.15; p-value: 0.006), ISG15-specific protease activity (Fold Enrichment: 146.79; p-value: 0.013), and nucleic acid binding (Fold Enrichment: 2.09; p-value: 0.015) related molecular functions were primarily enriched (As shown in Fig. 4 and Additional file 3: S3).

KEGG pathway analysis data appear in Fig. 4c. The results suggesting that the AF-DEGs were mainly enriched in pathways of cytokine–cytokine receptor interaction (p-value: 1.02E−04), cGMP-PKG signaling pathway (p-value: 0.025), antigen processing and presentation (p-value: 0.022), and NF-kappa B signaling pathway (p-value: 0.037). However, KEGG terms included PI3 K-Akt signaling pathway (p-value: 0.017) and B cell receptor signaling pathway (p-value: 0.045) were enriched in stroke-DEGs. (As shown in Fig. 4c and Additional file 4: S4). GO terms enrichment using the REACTOME database identified additional associations and these appear in Fig. 4d. The CTD database showed that Co-DEGs targeted several nervous system and cardiovascular diseases and these data appear in Fig. 5 and Additional file 5: S5.
Identification of functional and pathway enrichment among predicted miRNAs and Co-DEGs

Prediction analysis using mirDIP, miRDB, TargetScan, and DIANA bioinformatic tools identified the top 5 selected miRNAs targeting each Co-DEG involved in AF-related stroke and these data appear in Table 2. These data enable us to understand how predicted miRNAs are related to AF-related stroke progress.

**Discussion**

Predicting AF is needed for stroke prevention but 30% of patients have no signs of AF despite months of continuous cardiac rhythm monitoring. Thus, cardiovascular malignant events may be correlated with irregular and infrequent cardiovascular incidents as well as limitations in electromechanical indices that should predict problems with atrial contractility [7, 11, 12]. Estimating markers and associations between atrial dysfunction and embolic stroke are thus of interest and may be novel therapeutic targets for primary care. The inflammatory and immune response, and ion channel and transport are significantly associated with AF recurrence and maintenance, as well as the stroke occurrence. Several hub-genes involved directly or indirectly that regulate the nervous system were found among AF-DEGs. Visanji's group compared resting electrocardiograms of LRRK2-associated Parkinson's disease (PD) patients, nonmanifesting carriers, noncarriers, and idiopathic PD patients to investigate heart rate variability in LRRK2-associated PD [24]. There is evidence that LRRK2 may act as a bio-functional mediator to correlate heart rate variability and PD [24]. In a molecular mechanistic study, the neural protective role for regulating mitochondrial complex I function and oxidative stress in ischemia/reperfusion was identified [25, 26]. According gene–gene interaction analysis, Timasheva's group illustrated that the loci of CXCR2 is significantly associated with stroke development in patients with hypertension [26]. In addition, CXCR2 antagonism attenuated neurological deficits and infarct volumes via decreased cerebral neutrophil infiltration and peripheral neutrophilia in a hyperlipidemic ApoE−/− mice stroke model [27]. CALM1 is recognized as a major regulator of cardiac ion-current expression and calcium handling, and a key determinant of cardiac electrical function [28]. Also, specific risk alleles for CALM1 were identified as being associated with increased risk of stroke in studies of coronary heart disease [29]. Thus, there may be a relationship between cardiovascular and nervous system disease and they may arise from loci mutations or gene variants.

Additionally, PITX2, of the pituitary homeobox (Pitx) family, has a critical role in organ morphogenesis and AF maintenance which is related to short stature homeobox 2 (Shox2) [30]. Pitx2 is expressed in the LA and the pulmonary vein, which is considered a substrate and trigger for AF maintenance respectively. However,
several experimental data indicate a trend that PITX2 gene expression is silenced during aging in LA samples, suggesting genetic evidence for gene silencing for increased AF susceptibility [30, 31]. Then, miRNAs function analysis and a genomic approach showed that miR-17-92 and miR-106b-25 were associated with Pitx2 expression regulation and are implicated in human AF susceptibility [31]. To reveal relationships between genetic variants and the risk of ischemic stroke, Malik’s group studied PITX2 and ZFHX3 genes and found a significant association with cardioembolic stroke (CE) in a meta-analysis [31, 32]. Similarly, in a genome-wide association study using clinical samples from paroxysmal or persistent AF patients, ZFHX3 was significantly associated with LA enlargement and persistent AF and subsequently with ablation outcomes [33]. Correspondingly, Choi’s group found a significant association between top susceptibility loci (chromosomes 4q25 [PITX2], 16q22 [ZFHX3]) and AF recurrence after ablation in a Korean population, despite no top single nucleotide polymorphisms (SNPs) that predicted clinical recurrence after catheter ablation [34]. A regulatory role for PDZK1IP1 (MAP17) in reactive oxygen species production has been confirmed and is considered as a
marker for increased oxidative stress and may be a new therapeutic target [35], and recent research suggests a potential role for ions channels regulation, linked to the Na⁺/H⁺ exchanger 3 and A-kinase anchor protein 2/protein kinase A pathway [36]. However, ZNF566 plays a central role in heart regeneration and repair, and endocardial and epicardial epithelial to mesenchymal transitions [37, 38].

Research suggests potential beneficial effects of miRNA transformation therapy vectored by adenovirus, plasmid, and lentivirus for AF therapy [39]. We found that miR-27a-3p, miR-27b-3p, and miR-494-3p were co-DEGs and may be potential biomarkers of AF-related stroke. Interestingly, Vegter’s group compared heart failure-specific circulating miRNAs in 114 heart failure patients with/without different manifestations of atherosclerotic disease, and reported that miR-18a-5p, miR-27a-3p, miR-199a-3p, miR-223-3p and miR-652-3p abundance were associated with atherosclerosis and cardiovascular-related rehospitalizations [40]. Similarly, Marques and colleagues found that several miRNAs involved in let-7b-5p, let-7c-5p, let-7e-5p, miR-122-5p, and miR-21-5p, and absorbed miR-16-5p, miR-17-5p, miR-27a-3p, and miR-27b-3p are target pathways related to heart failure and considered to be potential biomarkers [41]. In contrast, expression of miR-27b-3p is significantly related to embryonic myogenesis and protein synthesis but miR-494-3p expression is associated with cerebral blood supply and functional recovery in a rat stroke model according to cerebral cortical miRNA profile changes [42, 43].

Conclusion
The hub-genes of LRRK2, CALM1, CXCR4, TLR4, CTNNB1, CXCR2, KIT, and IL1B may be associated with AF recurrence and maintenance and CD19, FGF9, SOX9, GNGTI, and NOG may be associated with stroke. Additionally, co-DEGs of ZNF566, PDZK1IP1, ZFHX3, and PITX2 link AF and stroke. Finally, the top 5 miRNAs for each co-DEGs may be potential biomarkers or therapeutic targets for AF-stroke, especially miR-27a-3p, miR-27b-3p, and miR-494-3p. Thus, there is an association between AF and stroke, and expression of ZNF566, PDZK1IP1, ZFHX3, and PITX2 genes favor AF-related stroke.

Limitation
Several limitations still detected in our study. First, this study is a microarray analysis that all the results based on gene expression value. However, owing to gene expression may be not directly equivalent to protein expression, the biomarkers of this study should consider as gene, not in protein. In application, assay of PCR and microarray chip may be better for accessing the risk of AF-related stroke. Second, validation should be carried out both in vitro, in vivo and clinical trials. However, as of now the techniques of in vitro or in vivo models for AF and stroke was immature. And the larger, prospective clinical studies may be better to validate our results to some extent.

Additional files
Additional file 1: S1. Differentially expressed genes involved in AF samples.
Additional file 2: S2. Differentially expressed genes involved in stroke.
Additional file 3: S3. Gene Ontology (GO) terms enrichment analysis of AF- and stroke-related differentially expressed genes.
Additional file 4: S4. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis among the AF- and stroke-related differentially expressed genes.
Additional file 5: S5. Relationship between diseases and co-expressed genes.

Abbreviations
AF: atrial fibrillation; DEGs: differentially expressed genes; GEO: gene expression omnibus; PPI: protein–protein interaction; GO: Gene Ontology; ARIC: atherosclerosis risk in communities; OXVASC: the Oxford vascular study; ASSERT: atrial fibrillation reduction atrial pacing trial; co-DEGs: co-expressed differentially expressed genes; AF-DEGs: AF-related differentially expressed genes; stroke-DEGs: stroke-related differentially expressed genes; miRNA: microRNA; LA: left atrial; RA: right atrial; SR: sinus rhythm; RMA: robust multi-array average; PM: perfect match; MM: mismatch probe; FDR: false discovery rate; FC: fold-changes; mirDIP: microRNA Data Integration Portal; KEGG: Kyoto Encyclopedia of Genes and Genomes; PD: Parkinson’s disease; Ptx: pituitary homeobox; Shox2: short stature homeobox 2; CE: cardioembolic stroke; SNPs: single nucleotide polymorphisms.

Authors' contributions
RZ, DZ, and LL: takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation, drafting the article. WS, ZS, BY, BL and QC: takes responsibility for statistical analyses, and interpretation of data. SY and PH: takes responsibility for full text evaluation and guidance, final approval of the version to be submitted. All authors read and approved the final manuscript.

Author details
1 Department of Cardio-Vascular Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China. 2 Department of Gastroenterology, Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai 519000, China. 3 Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China. 4 Department of Radiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China. 5 The Second Department of Orthopedics, Affiliated Hospital of Beihua University, Jilin 132011, China. 6 The Biobank of Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China. 7 Guangdong Province Key Laboratory of Brain Function and Disease, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China.

Acknowledgements
Not applicable.

Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
GSE79768 and GSE82944 datasets were downloaded from GEO (http://www.ncbi.nlm.nih.gov/geo/) [11] and expression profiling arrays were generated using GPL570 (HG-U133_Plus_2; Affymetrix Human Genome U133 Plus 2.0 Array, Affymetrix, Santa Clara, CA). R packages of `affy`, `affyPLM` and `limma` (http://www.biocodistro.org/packages/release/bioc/html/affy.html), provided by a bioconductor project [12], were applied to assess GSE79768 and GSE82944 RAW datasets. We applied online prediction tools utilizing microRNA Data Integration Portal (mirDIP) (http://ophid.utoronto.ca/mirDIP/ [13], mirDB (http://mirdb.org) [14], TargetScan (v7.1, http://www.targetscan.org/vert_71/) [15], and DIANA Tools (http://diana.imis.athena-innovation.gr/DianaTools/) [16], to predict potential microRNA targeting.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Not applicable.

Funding
This work was supported by the National Natural Science Foundation of China (NSFC, No. 81771165), the Natural Science Foundation Project in Guangdong province, China (Grant Nos. 2016A030313295, 2018A030313172) and Guangzhou Science and Technology project of Major Special Research Topics on International Collaborative Innovation (Grant Nos. 201704030032, 201807010010).

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 20 October 2018 Accepted: 4 February 2019
Published online: 13 February 2019

References
1. Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 2014;11(11):639–54.
2. Freeman AJ, Wang Y, Akar J, Desai N, Krumholz H. National trends in atrial fibrillation hospitalization, readmission, and mortality for Medicare beneficiaries, 1999–2013. Circulation. 2017;135(13):1227–39.
3. Thijs V. Atrial fibrillation detection: fishing for an irritable heartbeat before and after stroke. Stroke. 2017;48(10):2671–7.
4. Koton S, Schneider AL, Rosamond WD, Shahar E, Sang Y, Gottesman RF, Corey J. Stroke incidence and mortality trends in US communities, 1987 to 2011. JAMA. 2014;312(23):259–68.
5. Naghavi M, Abajobir AA, Abbafati C, Abbas KM, Abd-Allah F, Abera SF, Ackerman MA. Mortality and disability-adjusted life years in adults aged 20–64 years by cause, sex, regional, and age–sex-specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet (London, England). 2017;390(10055):1151–210.
6. Krishnamurthy RV, Moran AE, Feigin VL, Barker-Collo S, Norrving B, Mensah GA, Taylor S, Naghavi M, Forouzanfar MH, Nguyen G, et al. Stroke prevalence, mortality, and disability-adjusted life years in adults aged 20–80 years in 1990–2013: data from the global burden of disease 2013 Study. Neuroepidemiology. 2015;45(3):190–202.
7. Boehme AK, Esenwa C, Elkind MS. Stroke risk factors, genetics, and prevention. Circ Res. 2017;120(3):472–95.
8. Lip GY, Fauchier L, Freedman SB, Van Gelder I, Natalie A, Gianni C, Nattel S, Potparic T, Rienstra M, Tse HF, et al. Atrial fibrillation. Nat Rev Dis Primers. 2016;2:16016.
9. Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ, Becker RC, Singer DE, Halperin JL, Hacke W, et al. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF trial. Eur Heart J. 2015;36(5):288–96.
10. Yin GS, Howard DP, Paul NL, Li L, Luengo-Fernandez R, Bull LM, Welch SJ, Guttmikov SA, Mehta Z, Rothwell PM. Age–specific incidence, outcome, cost, and projected future burden of atrial fibrillation-related embolic vascular events: a population-based study. Circulation. 2014;130(15):1236–44.
11. Brambati M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C, Lui CP, Van Gelder IC, Holtzloser SH, Carlson M, et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation. 2014;129(21):2094–9.
12. Calenda BW, Fuster V, Halperin JL, Granger CB. Stroke risk assessment in atrial fibrillation: risk factors and markers of atrial myopathy. Nat Rev Cardiol. 2016;13(9):549–59.
13. Banett T, Wittke SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Philippy KH, Sherman PM, Holko M, et al. NCBI GEO archive for functional genomics data sets–update. Nucleic Acids Res. 2013;41(Database issue):D919–5.
14. Chen Z, McGee M, Liu Q, Scheuermann RH. A distribution free summarization method for Affymetrix GeneChip arrays. Bioinformatics (Oxford, England). 2007;23(3):321–7.
15. Pio G, Malerba D, D’Elia D, Ceci M. Integrating microRNA target predictions for the discovery of gene regulatory networks: a semi-supervised ensemble learning approach. BMC Biinformatics. 2014;15(Suppl 1):54.
16. Wong N, Wang X. mirDIP: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 2015;43(Database issue):D164–52.
17. Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs, eliFE. 2015. p. 4.
18. Paraksoupolou MD, Georgakiou K, Kostoulas N, Vlachos IS, Vergoulis T, Reczko M, Filippidis C, Dalamagas T, Hatzigeorgiou AG. DIANA-microRNA web server v5.0: service integration into miRNA functional analysis workflows. Nucleic Acids Res. 2015;43(Database issue):D164–52.
19. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Taiouf KF, et al. STRING v10: protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43(Database issue):D447–52.
20. da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.
21. Croft D, O’Kelly W, Wu G, Haw R, Gillespie M, Matthews L, Caudy M, Garapati P, Gopinath G, Jassal B, et al. Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res. 2011;39(Database issue):D691–7.
22. Munoz-Torres M, Carbon S. Get go! retrieving go data using AmiGO, QuickGO, API, Files, and Tools. Methods Mol Biol. 2017;1446:149–60.
23. Davis AP, Grondin CJ, Johnson RJ, Sicicky A, King BL, McMorran R, Wiegers J, Wiegers TC, Mattingly CJ. The comparative toxicogenomics database: update 2017. Nucleic Acids Res. 2017;45(D1):D972–d978.
24. Visanji NP, Bhudhikanok GS, Mestre TA, Ghati RC, Kark RT, Dhal AK, Connolly BS, Gasca-Salas C, Kern DS, Jain J, et al. Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson’s disease. Mov Disord. 2017;32(4):610–4.
25. Liu JI, Li TJ, Thomas JM, Pei Z, Jiang H, Engelerling S, Ross CA, Smith WW. Synphilin-1 attenuates mutant LRRK2-induced neurodegeneration in Parkinson’s disease models. Hum Mol Genet. 2016;25(4):672–80.
26. Timasheva YR, Nasibullin TR, Mustafina OA. The CXC2R Gene Polymorphism Is Associated with Stroke in Patients with Essential Hypertension. Cerebrovasc Dis Extra. 2015;5(3):124–31.
27. Herz J, Sabelnik P, Lane TE, Gunzer M, Herrmann DM, Doeppe TR. Role of neutrophils in exacerbation of brain injury after focal cerebral ischemia in hyperlipidemic mice. Stroke. 2015;46(10):2916–25.
28. Gaborit N, Le Bouteur S, Sauts V, Varro A, Escande D, Nattel S, Demolombe S. Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart. J Physiol. 2007;582(Pt 2):675–93.
29. Luke MM, O’Neeea ES, Rowland CM, Shiffman D, Bae LA, Aretano AR, Longstreth WT Jr, Lumley T, Rice K, Tracy RP, et al. Synphilin-1 attenuates mutant LRRK2-induced neurodegeneration in Parkinson’s disease models. Hum Mol Genet. 2016;25(4):672–80.
30. Timasheva YR, Nasibullin TR, Mustafina OA. The CXC2R Gene Polymorphism Is Associated with Stroke in Patients with Essential Hypertension. Cerebrovasc Dis Extra. 2015;5(3):124–31.
31. Herz J, Sabelnik P, Lane TE, Gunzer M, Herrmann DM, Doeppe TR. Role of neutrophils in exacerbation of brain injury after focal cerebral ischemia in hyperlipidemic mice. Stroke. 2015;46(10):2916–25.
32. Gaborit N, Le Bouteur S, Sauts V, Varro A, Escande D, Nattel S, Demolombe S. Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart. J Physiol. 2007;582(Pt 2):675–93.
32. Malik R, Traylor M, Pulit SL, Bevan S, Hopewell JC, Holliday EG, Zhao W, Abrantes P, Amouyel P, Attia JR, et al. Low-frequency and common genetic variation in ischemic stroke: the METASTROKE collaboration. Neurology. 2016;86(13):1217–26.

33. Hussier D, Buttner P, Lieberhammer L, Dinov B, Sommer P, Arya A, Hindricks G, Bollmann A. Association of atrial fibrillation susceptibility genes, atrial fibrillation phenotypes and response to catheter ablation: a gene-based analysis of GWAS data. J Transl Med. 2017;15(1):71.

34. Choi EK, Park JH, Lee JY, Nam CM, Hwang MK, Uhm JS, Joung B, Ko YG, Lee KH, Lutzitz SA, et al. Korean atrial fibrillation (AF) network: genetic variants for AF do not predict ablation success. J Am Heart Assoc. 2015;4(1):e002046.

35. Carnero A. MAP17 and the double-edged sword of ROS. Biochem Biophys Acta. 2012;1826(1):44–52.

36. Coady MJ, El Tarazi A, Santer R, Sasseville LJ, Calado J, Lubetra Y, Dumayne C, Bichet DG, Lussier Y, Lapointe JY. MAP17 Is a necessary activator of renal Na+/glucose cotransporter SGLT2. J Am Soc Nephrol. 2017;28(1):85–93.

37. Xin M, Olson EN, Bassel-Duby R. Mending broken hearts: cardiac development as a basis for adult heart regeneration and repair. Nat Rev Mol Cell Biol. 2013;14(1):529–41.

38. von Gise A, Pu WT. Endocardial and epicardial epithelial to mesenchymal transitions in heart development and disease. Circ Res. 2012;110(12):1628–45.

39. Friedman RC, Farhi KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19(1):92–105.

40. Vegter EL, Ovcinnikova ES, van Veldhuisen DJ, Jaarsma T, Berezovik E, van der Meer P, Voors AA. Low circulating microRNA levels in heart failure patients are associated with atherosclerotic disease and cardiovascular-related rehospitalizations. Clin Res Cardiol. 2017;106(8):598–609.

41. Marques FZ, Vizi D, Hammy M, Mariani JA, Kaye DM. The transcardiac gradient of cardio-microRNAs in the failing heart. Eur J Heart Fail. 2016;18(8):1000–8.

42. Lie S, Morrison JL, Williams-Wyss O, Suter WM, Humphreys DT, Oznarre SE, Zhang S, MacLaughlin SM, Kleemann DO, Walker SK, et al. Impact of peri-conceptional and preimplantation undernutrition on factors regulating myogenesis and protein synthesis in muscle of singleton and twin fetal sheep. Physiol Rep. 2015;3:8.

43. Zheng HZ, Jiang W, Zhao X, Du J, Liu PG, Chang LD, Li WB, Hu HT, Shi XM. Electroacupuncture induces acute changes in cerebral cortical miRNA profile, improves cerebral blood flow and alleviates neurological deficits in a rat model of stroke. Neural Regen Res. 2016;11(12):1940–50.